Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1115Gemcitabine 1058Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 678Radiotherapy 560Cetuximab 482pembrolizumab 437Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 280Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 223sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Carboplatin 191

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
TLC 388 × Gastrointestinal × Clear all
NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 2 Terminated
29 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔